3rd Annual Lab Asset & Facility Management in Pharma 2020
2020-11-10 - 2020-11-12 | Virtual Event
The 3rd Lab Asset & Facility Management in Pharma will return to Boston this Winter as your ONLY industry led meeting focusing on R&D asset and FM, enabling you to regain control of your assets, optimize your space and benchmark best practices to stay ahead of the curve.

Through strategic planning and rolling out digital tracking, Lab Asset, Operations and FM Directors are beginning to regain control of their inventory, asset value and optimize facility footprint to:

Reduce unnecessary downtime and ensure reliable business operations
Strengthen relationships and drive innovative partnership models with OEMs
Maximize asset lifecycle and value – and make informed financial decisions during purchasing, renewing, reselling and auctioning
Optimize lab and working space, implementing the ethos of shared economy within the R&D scientific community
Enhance capital efficiency to re-invest in drug development programs
Anticipate expansion from a lab and equipment perspective

Digital Neuropsychiatric Drug Development Summit
2020-11-10 - 2020-11-12 | Virtual Event
The 3rd Annual Neuropsychiatric Drug Development Summit will return in November 2020 as an interactive, virtual meeting. This definitive industry meeting is focused on helping you develop the next generation of more clinically effective therapeutics.

With an emphasis on depressive disorders, schizophrenia, addiction and PTSD, this timely meeting provides a much-needed platform for industry and academic thought leaders to:

Dive into novel therapeutic approaches for PTSD with Aptinyx, Bionomics, Tonix & MAPS
Uncover the emergence of the next generation of anti-psychotics with Karuna Therapeutics, NeuroRx & Intra-cellular Therapeutics
Explore industry approaches for innovative trial design and new methods to modelling the placebo response with Novartis, Otsuka & Yale University
Hear how pioneering biotechs are spearheading drug development for substance use disorders with Opiant Pharmaceuticals & the NIDA
Learn how to advance neurophysiology and cognition translational biomarkers and be part of the drive towards precision medicine with Takeda & UT Southwestern

Uniting 60+ drug developers from all corners of the world, Neuropsychiatric Drug Development is your opportunity to discuss in depth how to push forward the frontiers of neuropsychiatric drug development to develop the next generation of more clinically effective therapeutics.
To know more about Digital Neuropsychiatric Drug Development Summit please click here.

TIDES Europe: Oligonucleotide & Peptide Therapeutics 2020
2020-11-10 - 2020-11-13 | 100% Virtual
Europe’s #1 forum for oligonucleotide, peptide, CRISPR and mRNA therapeutic leaders to discuss scientific strategies and accelerate products to market, while also creating new successful partnerships. This year’s virtual agenda features 5 scientific tracks covering in-depth development strategies, trends and technologies across the entire oligonucleotide and peptide spectrum; as well as a partnering track that will keep you ahead of your competition, and work towards collaborations.

2nd Annual Biomarkers for Rare Non-Oncological Disorders
2020-11-10 | Digital Event
The Digital 2nd Annual Biomarkers for Rare Non-Oncological Diseases Summit will unite biopharma, diagnostic and healthcare teams to advance the application of precision medicine in rare diseases beyond oncology.
This event is completely free for Drug Developers, Researchers and Academics. To register your complimentary pass, simply follow this link: www.nononcologyraredisease-summit.com/take-part/register/
Tackling critical challenges from early research through to late-stage market access, this meeting is the must-attend summit for industry-led insights in delivering novel treatments for patients in need.
How Will it Help You Deliver Predictive Markers & Effective Drug-Dx Products?
Drawing on a multitude of disease areas spanning neurology, cardiology, metabolic, renal, inflammatory and more, the meeting combines a range of perspectives and experiences for unparalleled learning opportunities.
With 2 days of in-depth case studies, interactive panel discussions, dedicated Q+A time and valuable networking opportunities, you can walk away with improved end-to-end strategies from early biomarker validation to effective clinical trials and enabling successful regulatory, payer and commercial discussions.
Take a look at the full event guide to see all case studies, pre-conference workshop details and the full expert speaker faculty!

Microbiome Connect: Skin 2020
2020-11-10 - 2020-11-11 | Virtual Event
2019 proved to be a pivotal year for the skin microbiome, as personal care giants Unilever launched their Dove range of ‘microbiome-friendly’ skincare products. Clearly, the biggest players in beauty and personal care have recognised the potential commercial value of skin microbiome-based consumer product claims and formulations.

Moving forward into 2021, the market will continue to see more and more products launched with microbiome claims backed through next-generation sequencing techniques. Including ingestible beauty products that influence the gut-skin axis, to truly personalised skincare solutions and mass market formulations – there’s a huge commercial opportunity to commercialise skin microbiome research into consumer care products.
So, what’s different at Microbiome Connect: Skin EU Virtual?
Six new topics to explore:

The skin-gut axis and the development of ingestible beauty products.
Personalisation of skin-microbiome products and formulation considerations.
Defining skin-microbiome industry terminology and developing scientifically backed claims that resonate with consumers.
Next generation sequencing techniques and their application in claims development.
New data demonstrating the role of the microbiome in common skin conditions including acne, eczema and dandruff.
The vaginal and oral microbiomes and the mass market product development opportunities to treat gingivitis/periodontitis and sexually transmitted infections.

All tickets to tune into this event are 2FOR1 – simply quote this when booking online!

2nd Digital Exosome Based Therapeutic Development Summit
2020-11-11 - 2020-11-12 | Digital Event
The exosome therapeutics field is booming with anticipation as preparations are underway for the first few clinical trials and money pours in through partnerships and pipeline acquisitions. However, more is needed to be done to uncover more scientific knowledge, fine-tune manufacturing methods and prepare trials to meet regulatory expectations.
Considering this, the 2nd Digital Exosome Based Therapeutic Development Summit (November 11-12, 2020) will unite pharma, biotech, academic and technology providers to advance exosome therapeutics into a clinical and commercial reality.

This is your only industry-focused meeting dedicated specifically to evidence-based and regulated exosome-based therapeutics. Bringing together industry leaders and newcomers on the field, it’s two days not to be missed.
With 20+ speakers and 2 days of unrivalled in-depth content, join your peers to discuss:

End-to-end insights on drug development from discovery to scalable manufacturing of GMP-grade exosomes, clinical preparation, commercial strategy and more with Evox Therapeutics, Aruna Bio, Codiak Biosciences and ReNeuron
Innovations in exosome-based therapeutics, such as their applications in COVID-19 vaccines with Capricor Therapeutics
Understanding the underlying mechanisms of exosome interactions to inform target identification and development decisions with Scripps Research and University Hospital Essen
Preparing for clinical trials with key lessons learned from the best in the business such as Aegle Therapeutics
Over 4+ hours scheduled virtual networking time to connect with the community all from the comfort of your own home or office!

If you are exploring the therapeutic applications of exosomes in an evidence-based approach, this is the place for you.
Spanning 2 days, this digital program is tailor-made to showcase the field’s most exciting breakthroughs to inform your discovery, manufacturing, commercial and regulatory strategies. Join this interactive forum this November to drive GMP-grade manufacturing methods, consistent exosome production, improved isolation and purification, effective clinical and regulatory preparations, beneficial industry partnerships and more.
To know more about 2nd Digital Exosome Based Therapeutic Development Summit please click here.

Microbiome Connect: Human 2020
2020-11-12 | Virtual Event
Microbiome Connect: Human EU has been postponed this year due to the impacts of COVID-19. However, at Microbiome Connect, we’re committed to continue providing a platform for scientific presentations and networking opportunities for the microbiome community before we return to face-to-face again in 2021.

This November, we’ll be running a free-to-attend virtual symposium highlighting some of the latest scientific activity. Tune in for free on 12th November, 2020.
Agenda:
9.30 – 10:00 AM | Iron and the gut microbiome: an opportunity for LBPs functional during active gut inflammation
Jenny Bailey – CEO – Ferryx
10.15 – 10:40 AM | Gut-Brain axis mechanism of action and Clinical results on Hafnia alvei HA4597, a new probiotic strain for the regulation of appetite and weight management
Gregory Lambert – CEO – Targedys
10:55 – 11:20 AM | Rationally Designed Probiotic
Dr. Olaf Larsen – Senior Manager Science – Yakult Nederland B.V.
Register for free online.

4th Global Pharma R&D AI, Data Science and Informatics Summit
2020-11-16 - 2020-11-17 | London, UK
This Summit is designed to create a collaborative environment in which attendees engaged with the speakers, sponsors and other delegates in attendance. The meeting agenda has expanded to include:

AI for genomics, single-cell analysis and target validation.
AI for predicting patient response.
AI impacting clinical trials.
AI for imaging.
AI for cancer immunotherapy and neurodegenerative diseases,
Clinical informatics, data integration, management and storage,
Digital therapeutics, wearables and sensors.

With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

5th Medicinal Chemistry & Protein Degradation Summit
2020-11-16 - 2020-11-17 | London, UK
This Summit will focus its attention to some of the leading issues in Medicinal Chemistry today. This year the conference has expanded its coverage on protein degradation and will have a dedicated track running across both days to explore the cutting-edge research taking place in this exciting area.
The integration of AI and machine learning into the medicinal chemistry process is tackled in another track at the meeting with numerous case studies into how this developing technology is being utilized by industry leaders including Exscientia, Insitro and Bayer. This compliments the co-located informatics and AI meeting, which can be attended at any time, and examines artificial Intelligence in other parts of the drug discovery timeline.
Finally, the conference will be looking into recent advances and case studies in phenotypic screening and novel approaches to DNA encoded libraries within a dedicated track.
With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

2nd Annual Proteome- Targeted Drug Discovery Summit – Digital Event
2020-11-16 - 2020-11-18 | Virtual Event
With about 85% of the proteome currently undrugged, accessing these targets that are, at present, extremely difficult to drug, has prevented researchers from achieving desired clinical successes.
The 2nd Proteome- Targeted Drug Discovery Summit will unite large pharma and innovative biotech, as well as key opinion leaders in academia, to develop robust structural and biochemical tools to open up the full therapeutic opportunity held within the entire proteome. Identify and validate novel druggable sites and optimize structure-guided fragment-based drug design of small molecules with improved potency, selectivity, and physio-chemical properties.

Join the leading experts from the biopharmaceutical industry and academia to enhance your existing structural, chemical and computational toolbox and explore how these innovative technologies can be uniquely employed to target the entire proteome and advance your small molecule drug discovery pipeline.
Key Reasons to Attend Include

Utilize next-generation chemical biology platforms for novel target target identification with insights from Biogen, Merck & AstraZeneca
Expand the druggable proteome through next-generation screening platforms, with insight from GSK, PhoreMost & Ribon Therapeutics
Leverage innovative chemical probes to accelerate fragment-based lead generation, with insights from Novartis & The Weizmann Institute of Science
Harness structure-based computational technologies to successfully target protein-protein interactions, with insights from RAPT Therapeutics
Give rise to novel therapeutic modalities to drug the undruggable, with insights from Silicon Therapeutics& AbbVie

To know more about 2nd Annual Proteome- Targeted Drug Discovery Summit please click here.

4th Annual Antifibrotic Drug Development Summit
2020-11-16 - 2020-11-18 | Virtual Event
Solving the Translational Drug Development Gap, From Fibrotic Mechanisms to Clinically Effective Therapeutics.
Now in its 4th year, the digital AFDD summit is the industry’s definitive guide to turning mechanistic understanding of fibrosis into clinically effective therapeutics across disease areas. With 3 days of in-depth cutting-edge case studies and the highest calibre of discussions from cross-disciplinary fibrosis heavy-weights, AFDD will bridge the current translational gap to anti-fibrotic drug development success
Join 100+ fibrosis experts at this fully digital event to build a comprehensive network with like-minded peers and hurdle your translational drug development challenges to accelerate the development of more clinically effective drugs.
To know more about 4th Annual Antifibrotic Drug Development Summit please click here.

3rd Lifecycle Management for Combination Products Summit
2020-11-16 - 2020-11-18 | Virtual Event
The 3rd Lifecycle Management for Combination Products Summit is the only dedicated meeting focusing on Lifecycle Management (LCM) and perfecting design control. This year the meeting will unite senior combination products leaders online to discuss strategies and lessons learned to help you ensure commercial competitiveness in the combination product markets. From quality and product development, to CMC and regulatory affairs, our experts speakers will help you delve into how to produce a quality and safe combination product, implications of EU MDR and the final implementation phase of post-market surveillance reporting.
To know more about 3rd Lifecycle Management for Combination Products Summit please click here.

Clinical Operations in Oncology Trials USA 2020: Virtual Conference
2020-11-17 - 2020-11-18 | Virtual Event, CA
As the industry grapples with unprecedented challenges, join us for our first ever Clinical Operations in Oncology Trials USA Virtual Experience brought to you directly in the comfort of your home! Bringing together experts from across the country to discuss the latest innovations in technology, regulatory affairs as well as discover new opportunities through adaptive approaches and methods to run successful clinical trials.

To know more about Clinical Operations in Oncology Trials USA 2020 please click here.

CRISPR 2.0
2020-11-17 - 2020-11-19 | Digital Congress
Discover the Next Generation of CRISPR Tools to Enhance Specificity, Reduce Off-Target Effects & Transform Gene Editing into a Clinical Reality
CRISPR is one of the most powerful discoveries of the last decade.
In a remarkably short space of time, ‘classic’ CRISPR-Cas9 has established itself as a reliable tool in the genomics toolbox, which leads to the question: what’s next?
CRISPR 2.0 is the industry-leading meeting dedicated to answering this question by showcasing only the latest and greatest innovations in CRISPR technology, from the potential of prime editing through to epigenome editing to treat chronic pain.
Don’t get left behind. Join leading pharma and biotech companies pioneering CRISPR-based therapeutics into the clinic and academic organizations breaking new ground in establishing novel CRISPR tools.
Join us to usher in the next generation of safe, targeted and effective genome editing.
For more information on the conference, visit https://ter.li/ok8ifs
“Thank you for having me. I have attended all CRISPR Congresses and they keep getting better” John Sundman, Past attendee, CRISPR Event Series
” I greatly enjoyed the diversity and topic coverage of the talks, thanks for putting together an excellent program!” Christina Kolodzy, Past attendee, CRISPR Event Series
“A high-quality worthwhile conference, attended by first rate professionals. I learned more than I anticipated I would” Past attendee, CRISPR Event Series

CPhI & P-MEC China Virtual Expo Connect
2020-11-18 - 2020-12-18 | Virtual Event powered by CPhI China & Pharmasources.com
As well as the physical CPhI & P-MEC China 2020 show that will take place in Shanghai from 16th – 18th December, a digital extension of the event – known as “Virtual Expo Connect” – will take place online from November 18th – December 18th, allowing you to do business in China, no matter your location. The hybrid “Virtual Expo Connect” offers an online alternative for international visitors unable to travel to the physical show in China due to travel restrictions, adding valued services and infinite opportunities to connect, learn, trade and grow.
CPhI & P-MEC China Virtual Expo Connect
A hybrid offline-2-online platform for global pharma professionals
Nov 18 – Dec 18, 2020
To know more about CPhI & P-MEC China Virtual Expo Connect please click here.

Digital Pathology & AI Congress: USA
2020-11-19 - 2020-11-20 | New York, USA, United States
This meeting has a reputation for providing an outstanding networking experience. Discover how to effectively harness gains such as reducing lab costs, improving links with other laboratories and scientists, and minimizing human error.

Topics covered on the agenda include:

How AI is being applied to primary diagnosis and clinical research.
AI for image analysis and advancements in imaging
Computational pathology and AI
Implementation: practicalities and costs
Pharma and industry case studies

With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

Women and Infant Health Microbiome Congress
2020-11-19 - 2020-11-20 | London, UK
With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

Digital Agenda Revealed: 9th HPAPI Summit
2020-11-19 - 2020-11-20 | Virtual Event
As the world around us evolves, we want to ensure we can still unite you and your peers in highly potent API development and manufacturing.
We are excited to have transformed the 9th HPAPI Summit into a fully digital meeting running on November 19-20.
Thanks to our dedicated speakers, we’re still able to deliver the high-quality content and networking opportunities that you need to advance your high potent strategy in your company, from development to containment to EHS and outsourcing.
And the best part? As a giving back to our long standing HPAPI community, pharma, biotech and academia can now register for free!
Solution provider rate starts from $1,259, register by August 7 to save up to $280.
Download the new digital event program here.
Here’s a glimpse at some of the expert speakers confirmed to present:

Christopher Sears, Senior Director, CMC Tarveda Therapeutics
Cornelia Rudolph, Clean Water DG Environment, European Commission
Graeme McKilligan, Lead Senior GMDP Inspector, MHRA
Mirjam Sax, Principal Site Manager, Genentech
Dave Eherts, Vice President Global EHS, Allergan
Andrew Hopkins, Director, Operation Quality, QA Audit & Compliance, AbbVie
John Roosa, Director, New Technology Development & Industrial Hygiene Engineer, Merck

Our bespoke virtual conference platform will allow you to network with industry colleagues, evaluate new suppliers and the latest technology HPAPI containment and participate in live Q&A with speakers. For more details see here.
We hope to see you there!

In-House Impact: Life Sciences 2020 – Virtual Event
2020-11-19 - 2020-11-20 | Virtual Event
Redefining In-House Counsel as Innovator & Strategic Partner, Maximizing & Benchmarking Legal Business Value to Set the New Standard for Today’s Life Sciences Lawyer.
In-House Impact works because it connects you with the most forward-thinking legal leaders taking the most radical steps to maximize the business value they add as strategic business partners.
With thought-provoking case studies, action-led discussions and ensuring every story shared is evidenced by the business improvement it delivers, we guarantee that your time and your money are well spent.
This conference isn’t just unique in offering an industry-specific platform for the most progressive legal leaders to maximize their own business value; it’s also unique in that it rips up the rulebook of traditional conferences.
We believe the traditional conference format is no longer fit for purpose, so we started from scratch.

Here’s how it works:
When you look at the event agenda, you will see three main types of sessions:

Discover sessions offer you the chance to hear the boldest legal leaders in Life Sciences sharing the stories of what they’re doing to maximize the impact of their team
Develop sessions provide you with the unique opportunity to have your burning questions answered in a room full of your peers and move beyond the ‘what’ and the ‘why’ to get to the ‘how’
Action sessions divide the audience by same-level seniority, and are designed to help you discuss challenges with peers, and decide what you are going to change in order to add as much value to the business

In-House Impact: Life Sciences is a new event, both designed by and for General Counsels of Life Sciences companies, from smaller start-ups to large pharmaceuticals.
For more information visit https://ter.li/cata3o, or contact the team via email at info@hansonwade.com.

*NEW* Translating Documentation & Communication Clinical Research: Virtual Conference
2020-11-24 | Virtual Event, CA
This one-day online event will deliver top-quality content and engagement covering all aspects of language operations for clinical research: clinical trial protocols, informed consent, site documents, regulatory submissions and correspondence, labeling, IFUs, patient correspondence, and much more.

To know more about Translating Documentation & Communication Clinical Research please click here.

Cost-efficient and Green Manufacturing of Peptides thanks to Molecular Hiving™ Technology
2020-11-26 | Online Webinar
HOSTED BY: Bachem Group
LED BY: Dr. Wolfgang Seufert, Director Production III – Process Development, Bachem
Bachem and Jitsubo CO., Ltd. recently announced the signature of an exclusive Licensing Agreement for Jitsubo’s Molecular Hiving™ Technology. Under the License agreement, Jitsubo will develop selected manufacturing processes using their Molecular Hiving™ Technology and transfer these processes to Bachem. Bachem will further optimize, scale up and produce for commercial applications.

Molecular Hiving™ is a tag-assisted liquid-phase peptide synthesis technology developed by Professor Kazuhiro Chiba at Tokyo University of Technology and Agriculture. This technology uses a hydrophobic tag, which is applied in the same way as the resin for solid-phase peptide synthesis (SPPS) processes. The same standard Fmoc amino acid derivatives as for SPPS are applied for assembling the peptide chain. However, all couplings and cleavages of the Fmoc protecting group are performed in solution allowing for fast reactions and direct in-process controls, e.g. by HPLC. Excess reagents as well as coupling and cleavage related by-products are solely removed by aqueous extractions. Therefore, intermediate isolation of the tag-bound peptide and excessive washing steps are not required for Molecular Hiving™ Technology.
In this webinar, the speaker will guide you through the individual steps for synthesis of peptides applying Molecular Hiving™ Technology. You will learn about the scalability and the substantial advantages of this technology regarding efficiency and towards greener manufacturing, as solvent consumption and material requirements are significantly reduced compared to conventional SPPS processes. Molecular Hiving™ also allows the synthesis of peptides without the use of solvents and reagents which are carcinogenic, mutagenic, or toxic to reproduction (CMR substances). This makes peptide products manufactured by this technology highly attractive for the pharmaceutical and cosmetics industry.
Benefits for Joining the Webinar:

Hear about Bachem’s partnership with Jitsubo
Discover how to synthesize peptides by Molecular Hiving™ Technology
Explore the advantages and the environmental benefits of Molecular Hiving™ Technology
Learn about manufacture of peptides without CMR solvents and reagents

Who should attend?
Scientists in Pharma, Biotech, Cosmetics industry, and Universities including:

Research Scientists and Associates
PostDocs and PhDs
Scientific Advisors
Directors of Research and Development

Other Professionals in the Life Sciences including Product Managers and Marketing Managers

2nd Annual Gene Therapy Analytical Development | Running Digitally for 2020
2020-11-30 - 2020-12-03 | Virtual Event
Optimizing Analytical Methods to Guarantee Safe, High Quality, Consistent & Efficacious Gene Therapy Products
In the context of rapid gene therapy progress and mounting regulatory scrutiny, the 2nd Annual Gene Therapy Analytical Development Summit will virtually unite large pharma and innovative biotechs to discuss the full and comprehensive range of analytical tools required to guarantee the consistency, quality and safety of gene therapy products.

Focused specifically on addressing the unique analytical challenges posed by gene therapy vectors, this technical scientific conference will unite the Analytical Development, QC, CMC, and Process Development leaders grappling with these challenges first-hand.
Incorporating tracks taking a deep dive into bioassays, molecular biology, and analytical chemistry, this is your opportunity to gain extensive technical information enabling you to solve the exact challenges you’re encountering. Enhance your existing analytical methods and explore innovative novel tools to support safe and effective gene therapy development.
To know more about 2nd Annual Gene Therapy Analytical Development please click here.

2nd RNA Editing Summit 2020
2020-12-01 - 2020-12-03 | Virtual Event
RNA Editing is reaching an inflection point and is rapidly being discussed, invested in and adopted by the industry.
This year, in an all new digital format, the timely 2nd RNA Editing Summit returns as the only industry led meeting showcasing the recent developments of RNA editing mechanisms and dedicated to realizing the research and therapeutic opportunity of RNA editing as quickly as possible.

This meeting offers a wealth of relevant content covering everything from basic RNA biology and the fundamentals of RNA editing through to mitigating against off target activity to the plethora of clinical applications.
Join industry leaders from the likes of InsideOutBio, Edigene, Locano Bio and more to:

Hear the current strategies of site directed RNA editing from A – I to C – U to CRISPR based
Understand how to mitigate off target-activity without critically effecting the efficiency of the on target edit in the transcript
Ensure the safety and stability of your edit whilst maintaining efficiency and safe guard against potential toxic events
Assess how to develop RNA editing technologies in preclinical models to ensure the system works as intended in the human body
Delve into the different delivery mechanisms available to ensure the protein molecules that do the editing make it into the cells
Identify the latest clinical applications of RNA Editing, reviewing the structures and functions of ADARs, CRISPR CAS 13, APOBEC and their involvements in human diseases

To know more about 2nd RNA Editing Summit 2020 please click here.

Neuromuscular Drug Development Summit
2020-12-01 - 2020-12-02 | Virtual Event
Validate Clinically Meaningful Endpoints, Optimize Clinical Trial Design & Compare & Contrast Diverse Approaches to Accelerate the Discovery & Development of Meaningful Treatments for Patients in Need

The 3rd Neuromuscular Drug Development Summit presents a unique opportunity to:

Uncover the right outcome measures to use in your clinical trial and discover how to establish clinical meaningfulness with Biogen
Hear approaches to optimizing therapeutic efficacy in SMA, an innovative approach to trial design for real world SMA population and how combinatorial treatments may improve SMA treatment outcomes with Roche, PTC Therapeutics and John Hopkins University School of Medicine
Assess emerging neurophysiological methods for more quantitative, faster readouts and the need to explore digital capture tools to improve therapeutic R&D with Harvard Medical School and the Parent Project Muscular Dystrophy (PPMD)
Dissect various dosing strategies and discuss how to demonstrate a clear mechanistic route between dose, mechanisms of action and endpoints with NMD Pharma and Argenx
Evaluate the role of biomarkers, how regulatory agencies approach the integration of biomarkers in clinical trials and biomarker outcome measures outside dystrophin with ReveraGen Biopharma and the Critical Path Institut
Hear how Avidity Biosciences are developing an oligonucleotide antibody conjugate for the treatment of DM1

Uniting drug developers and academics from all corners of the world, the virtual Neuromuscular Drug Development Summit is your opportunity to discuss recent advances in this fast-evolving field, convey lessons learned and network to build long lasting partnerships.

7th Microbiome & Probiotics R&D & Business Collaboration Forum: Europe
2020-12-02 - 2020-12-03 | Rotterdam, The Netherlands
In response to COVID-19, this meeting will be hosted online using the latest digital technology. Network with your peers, ask questions of the speakers, and meet with the sponsors from the safety of your home or office.
This forum has a long-standing reputation for bringing together leading academic and industry microbiome researchers. Presentations will feature the latest research into the human microbiome as well as effective business and commercialization strategies for new products.
Topics covered on the agenda include:

IBD, Colitis, and Metabolic Diseases
Gut-brain axis
Women’s health
Skin & Cosmeceuticals
Personalized nutrition
Business Collaboration – Regulations & Investment
Probiotics & Prebiotics
Roundtable discussions

With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

Clinically Validated Digital Therapeutics Summit
2020-12-02 - 2020-12-03 | Virtual Event
As the world opens up to digital health, now is the time to design, develop & deliver clinically validated digital therapeutics to patients in need. Back for its 3rd year, the Clinically Validated Digital Therapeutics Summit will unite more stakeholders than ever before. Explore newcomers in the world of DTx, showcasing never before shared case studies. This meeting will solely focus on the actionable uses of digital therapeutics to deliver radically improved patient outcomes.
Integrating brand new lessons learned from the COVID 19 pandemic, the 2020 summit will drive the DTx industry forward with case studies that tackle a multitude of disease areas and therapeutic modalities, from prescription and chronic disease management to care bundles, concomitant therapy and preventive medicine. Covering the full spectrum, the 2020 summit will address challenges around clinical trials, regulatory approval, reimbursement and value application in healthcare.
View the Full Event Guide Here.

7th Digital Pathology & AI Congress: Europe
2020-12-03 - 2020-12-04 | London, UK
This meeting has a reputation for providing an outstanding networking experience in which you can discover how to effectively harness gains such as reducing lab costs, improving links between other laboratories & scientists and minimizing human error.

Over two days you will discover more about the latest advances and applications of digital pathology, including:

How artificial intelligence and machine learning is being applied to primary diagnosis and clinical research.
How the image-based information environment is transforming the laboratory.
AI for image analysis and advancements in imaging.
Computational pathology and AI.
Implementation: practicalities and costs.
Pharma and industry case studies.

With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

BioFIT 2020
2020-12-07 - 2020-12-10 | Virtual Event
Come and join us online for the 9th edition of BioFIT, from the 7th to the 10th of December 2020!
With the highest attending rate of TTOs, research institutes and academia together with big pharma, emerging and small biotech, diagnostics companies, pre-seed / seed / Series A investors, BioFIT is the leading partnering event in Europe for technology transfer, academia-industry collaborations and early-stage innovation deals in the field of Life Sciences. BioFIT is also the European marketplace for pre-seed, seed and Series A investment in Life Sciences.

KEY FIGURES:

1,400+ delegates
900+ organisations
40+ countries represented
1,000 deals generated in 2017

INSIDE THE EVENT:

A business convention with pre-qualified one-to-one meetings
Conferences and roundtable discussions
Oral presentations of start-ups and licensing opportunities stemming from academia
An exhibition area
Informal networking evenings

Across these 4 days of event, you will be able to e-meet and network with these attendees from the comfort of your home office. The one-to-one partnering meetings will be possible 24H a day.
You will also have access, for the conferences and the pitch sessions, to a mix of live and on-demand content during those 4 days and available for 30 days afterwards; and you will also have the opportunity to debate with the speakers and pitchers via interactive online chats.
Website: www.biofit-event.com
Registration: www.biofit-event.com/registration-for-biofit/
Contact: msatola@eurasante.com

2nd Annual Gene Therapy for Neurological Disorders | Running Digitally for 2020
2020-12-08 - 2020-12-10 | Vitual Event
Revolutionize the Development & Delivery of Neurological Gene Therapies
Returning this year as a digital meeting with an agenda designed with the field’s thought-leaders including Pfizer, Biogen, Voyager and Novartis, the 2nd Annual Gene Therapy for Neurological Disorders is the industry’s only meeting dedicated to solving your translational drug development challenges, enabling you to accelerate the development of your neurological gene therapy candidate.
Don’t get left behind. Attend this meeting to transform gene therapy delivery to the CNS, optimize translational modelling approaches and discover targeted, efficacious, and safe vectors to revolutionize the treatment of neurological disorders.
To learn more about Gene Therapy for Neurological Disorders please click here: https://ter.li/c610sy

3rd RNA-Targeted Drug Discovery Summit
2020-12-08 - 2020-12-10 | Digital Event
The 3rd RNA- Targeted Drug Discovery Summit returns as the most comprehensive and definitive event for the RNA targeting small molecule community to not only address key challenges of the field, such as successful determination and prediction of RNA structure and role in disease, but also to drive forward optimized strategies to improve target selection and gain pre-clinical proof of concept to drive the field forward towards translation into clinical development.

With numerous approaches emerging to demonstrate genuine viability in directly or indirectly targeting RNA with small molecules, join leading biopharmaceutical directors, VPs and C-level executives at the 3rd RNA- Targeted Drug Discovery Summit – your premier industry and translational focused conference dedicated to advancing pioneering RNA biology and drug discovery into a blockbuster RNA targeting small molecule therapeutic approach that improves patient outcomes.
The world of drug discovery and chemical probes is still protein-centric and developing highly selective small molecules targeting RNA is often considered to be an insurmountable challenge. This view is now changing given the recent progress and scientific breakthroughs in understanding the fundamental biology and function of RNA, opening the door to RNA targeted small molecule drug discovery.

Explore how to optimize medicinal chemistry insights & RNA biology to enhance robust translation with The Scripps Research Institute, Anima Biotech & Arrakis Therapeutics

Successfully target RNA via interfering with RNA-protein interactions/ Epitranscriptomics with insights from Storm Therapeutics, Accent Therapeutics & Saverna Therapeutics

Expand your knowledge of RNA structure, function & role in disease with insights from Yale University, H3 Biomedicine & Whitehead Institute for Biomedical Research

Advance identification & validation of viable RNA target sites for therapeutic intervention with insights from PTC Therapeutics & Duke University

Overcome binding, selectivity & drug-like challenges of small molecules targeting RNA with insights from Roche, University of California San Diego & Novartis

To know more about 3rd RNA-Targeted Drug Discovery Summit please click here.
